Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyHoward I. Scher, Charles L. Sawyers, Tomasz M. Beer et al.|The Lancet|2010Cited by 1.1k
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid CancerAlan L. Ho, James A. Fagin, Ravinder K. Grewal et al.|New England Journal of Medicine|2013Cited by 825
Long-Term Prognostic Significance of Extent of Rectal Cancer Response to Preoperative Radiation and ChemotherapyLeyo Ruo, José G. Guillem, Satish K. Tickoo et al.|Annals of Surgery|2002Cited by 284
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate CancerDana E. Rathkopf, Howard I. Scher, Michael J. Morris et al.|Journal of Clinical Oncology|2013Cited by 264
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug DevelopmentGary J. Kelloff, Janet Woodcock, Kenneth A. Krohn et al.|Clinical Cancer Research|2005Cited by 220